Meet the Team
Grannus Therapeutics is led by a team of experienced biotech executives, translational researchers, and oncology innovators with a shared goal: to deliver smarter, safer, and more effective cancer treatments.
First-in-Class, Cancer Therapy Solutions
Grannus is creating a new generation of Hsp90 inhibitors that are selective to the beta isoform or version of the Hsp90 protein. Designed to deliver potent single-agent efficacy and unlock powerful combinations with other approved therapies such as PARPi, giving more patients access to new treatments.
Unlocking full potential
A new solution for an old problem
Hsp90 has long been recognized as a promising cancer target, but previous therapies lacked isoform selectivity, resulting in dose-limiting toxicities and disappointing efficacy that halted development.
Hsp90β Selectivity
> 100 fold selective to Hsp90β vs other isoforms
PK/ADME Profile
> 50% oral bioavailability with preferential tumor biodistribution
Efficacy Profile
Oral in vivo POC in overian cancer, and additional data in other tumors
Clean Tox Profile
What makes our approach different is selectively inhibiting the beta isoform, creating a clean toxicity profile.
Strong IP Protection
Issued US patent protection through 2039, with provisional filings extending protection to 2045.
Grannus’s approach is different, by selectively inhibiting the beta isoform, we have overcome the limitations of previous non-selective drugs, unlocking the full potential of the Hsp90 target. Our first-in-class Hsp90β-selective inhibitor delivers potent anti-tumor activity with a clean safety profile.
Breakthrough Science,
Real Momentum
Backed by strong preclinical data and preferential tumor biodistribution
we are moving rapidly toward IND-enabling milestones and clinical studies.
We’re reigniting a once-promising therapeutic strategy.
Our team has a proven track record of advancing therapies from concept to clinic.
Join Our Mission to
Transform Cancer Care
Our lead candidate, GRE317, demonstrates robust single-agent efficacy while enabling powerful combinations with PARP inhibitors and immunotherapies.
Leadership Team
A Unique Opportunity to Advance Oncology Innovation
Partner with Grannus to advance first-in-class Hsp90β-targeted cancer therapies
